{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:37:37Z","timestamp":1782923857689,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32-HL7627-34"],"award-info":[{"award-number":["5T32-HL7627-34"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM007205"],"award-info":[{"award-number":["T32GM007205"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00262-018-2241-x","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T09:29:40Z","timestamp":1536226180000},"page":"1833-1844","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies"],"prefix":"10.1007","volume":"67","author":[{"given":"Allison S.","family":"Dobry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl K.","family":"Zogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Stephen","family":"Hodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1405-3667","authenticated-orcid":false,"given":"J. Bryan","family":"Iorgulescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,6]]},"reference":[{"key":"2241_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7\u201330. \n                    https:\/\/doi.org\/10.3322\/caac.21332","journal-title":"CA Cancer J Clin"},{"key":"2241_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/jamadermatol.2016.4512","volume":"153","author":"AM Glazer","year":"2017","unstructured":"Glazer AM, Winkelmann RR, Farberg AS, Rigel DS (2017) Analysis of trends in US melanoma incidence and mortality. JAMA Dermatol 153:225\u2013226. \n                    https:\/\/doi.org\/10.1001\/jamadermatol.2016.4512","journal-title":"JAMA Dermatol"},{"key":"2241_CR3","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S0140-6736(13)60802-8","volume":"383","author":"AM Eggermont","year":"2014","unstructured":"Eggermont AM, Spatz A, Robert C (2014) Cutaneous melanoma. Lancet 383:816\u2013827. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(13)60802-8","journal-title":"Lancet"},{"key":"2241_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/ITT.S110479","volume":"6","author":"J Force","year":"2017","unstructured":"Force J, Salama AK (2017) First-line treatment of metastatic melanoma: role of nivolumab. ImmunoTargets Ther 6:1\u201310. \n                    https:\/\/doi.org\/10.2147\/ITT.S110479","journal-title":"ImmunoTargets Ther"},{"key":"2241_CR5","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","volume":"17","author":"PA Ascierto","year":"2016","unstructured":"Ascierto PA, McArthur GA, Dr\u00e9no B et al (2016) Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17:1248\u20131260. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(16)30122-X","journal-title":"Lancet Oncol"},{"key":"2241_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1056\/NEJMoa1112302","volume":"366","author":"JA Sosman","year":"2012","unstructured":"Sosman JA, Kim KB, Schuchter L et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707\u2013714. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1112302","journal-title":"N Engl J Med"},{"key":"2241_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ et al (2018) Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 19:603\u2013615. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(18)30142-6","journal-title":"Lancet Oncol"},{"key":"2241_CR8","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","volume":"19","author":"PA Ott","year":"2013","unstructured":"Ott PA, Hodi FS, Robert C (2013) CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19:5300\u20135309. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0143","journal-title":"Clin Cancer Res"},{"key":"2241_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"key":"2241_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","volume":"11","author":"JD Wolchok","year":"2010","unstructured":"Wolchok JD, Neyns B, Linette G et al (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11:155\u2013164. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(09)70334-1","journal-title":"Lancet Oncol"},{"key":"2241_CR11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","volume":"18","author":"PA Ascierto","year":"2017","unstructured":"Ascierto PA, Del Vecchio M, Robert C et al (2017) Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 18:611\u2013622. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(17)30231-0","journal-title":"Lancet Oncol"},{"key":"2241_CR12","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521\u20132532. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"key":"2241_CR13","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006\u20132017. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1414428","journal-title":"N Engl J Med"},{"key":"2241_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23\u201334. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"key":"2241_CR15","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377:1345\u20131356. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1709684","journal-title":"N Engl J Med"},{"key":"2241_CR16","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507\u20132516. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1103782","journal-title":"N Engl J Med"},{"key":"2241_CR17","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long GV, Stroyakovskiy D, Gogas H et al (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386:444\u2013451. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(15)60898-4","journal-title":"Lancet"},{"key":"2241_CR18","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","volume":"371","author":"GV Long","year":"2014","unstructured":"Long GV, Stroyakovskiy D, Gogas H et al (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371:1877\u20131888. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1406037","journal-title":"N Engl J Med"},{"key":"2241_CR19","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J, Ascierto PA, Dr\u00e9no B et al (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:1867\u20131876. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1408868","journal-title":"N Engl J Med"},{"key":"2241_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J et al (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:30\u201339. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1412690","journal-title":"N Engl J Med"},{"key":"2241_CR21","unstructured":"National Comprehensive Cancer Network (2018) NCCN clinical practice guidelines in oncology: Melanoma version 2.2018. National Comprehensive Cancer Network. \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#melanoma\n                    \n                  . Accessed 1 Mar 2018"},{"key":"2241_CR22","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jamaoncol.2015.1184","volume":"1","author":"J Larkin","year":"2015","unstructured":"Larkin J, Lao CD, Urba WJ et al (2015) Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol 1:433\u2013440. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2015.1184","journal-title":"JAMA Oncol"},{"key":"2241_CR23","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/jnci\/djv414","volume":"108","author":"MB Atkins","year":"2016","unstructured":"Atkins MB, Larkin J (2016) Immunotherapy combined or sequenced with targeted therapy in the treatment of solid tumors: current perspectives. J Natl Cancer Inst 108:414. \n                    https:\/\/doi.org\/10.1093\/jnci\/djv414","journal-title":"J Natl Cancer Inst"},{"key":"2241_CR24","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:908\u2013918. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(15)00083-2","journal-title":"Lancet Oncol"},{"key":"2241_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375\u2013384. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(15)70076-8","journal-title":"Lancet Oncol"},{"key":"2241_CR26","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","volume":"17","author":"JS Weber","year":"2016","unstructured":"Weber JS, Gibney G, Sullivan RJ et al (2016) Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol 17:943\u2013955. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(16)30126-7","journal-title":"Lancet Oncol"},{"key":"2241_CR27","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","volume":"17","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Chesney J, Pavlick AC et al (2016) Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17:1558\u20131568. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(16)30366-7","journal-title":"Lancet Oncol"},{"key":"2241_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ctrv.2017.01.006","volume":"54","author":"S Pasquali","year":"2017","unstructured":"Pasquali S, Chiarion-Sileni V, Rossi CR, Mocellin S (2017) Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: a network meta-analysis. Cancer Treat Rev 54:34\u201342. \n                    https:\/\/doi.org\/10.1016\/j.ctrv.2017.01.006","journal-title":"Cancer Treat Rev"},{"key":"2241_CR29","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","volume":"3","author":"DJ Boffa","year":"2017","unstructured":"Boffa DJ, Rosen JE, Mallin K et al (2017) Using the national cancer database for outcomes research: a review. JAMA Oncol 3:1722\u20131728. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2016.6905","journal-title":"JAMA Oncol"},{"key":"2241_CR30","volume-title":"Pathology and genetics of skin tumours","author":"PE LeBoit","year":"2006","unstructured":"LeBoit PE, Burg G, Weedon D, Sarasain A (2006) Pathology and genetics of skin tumours, 3rd\u00a0edn. IARC Press, Lyon","edition":"3"},{"key":"2241_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/2326-6066.CIR-18-0067","volume":"6","author":"JB Iorgulescu","year":"2018","unstructured":"Iorgulescu JB, Harary M, Zogg CK et al (2018) Improved risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: results from a national cohort. Cancer Immunol Res 6:1\u20137. \n                    https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0067","journal-title":"Cancer Immunol Res"},{"key":"2241_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnci\/djv294","volume":"108","author":"WR Shaikh","year":"2016","unstructured":"Shaikh WR, Dusza SW, Weinstock MA et al (2016) Melanoma thickness and survival trends in the United States, 1989\u20132009. J Natl Cancer Inst 108:1. \n                    https:\/\/doi.org\/10.1093\/jnci\/djv294","journal-title":"J Natl Cancer Inst"},{"key":"2241_CR33","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1245\/s10434-012-2398-z","volume":"19","author":"JH Howard","year":"2012","unstructured":"Howard JH, Thompson JF, Mozzillo N et al (2012) Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol 19:2547\u20132555. \n                    https:\/\/doi.org\/10.1245\/s10434-012-2398-z","journal-title":"Ann Surg Oncol"},{"key":"2241_CR34","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ijrobp.2013.08.035","volume":"88","author":"CA Barker","year":"2014","unstructured":"Barker CA, Postow MA (2014) Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. Int J Radiat Oncol Biol Phys 88:986\u2013997. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2013.08.035","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2241_CR35","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/jid.2010.354","volume":"131","author":"A Joosse","year":"2011","unstructured":"Joosse A, de Vries E, Eckel R et al (2011) Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Investig Dermatol 131:719\u2013726. \n                    https:\/\/doi.org\/10.1038\/jid.2010.354","journal-title":"J Investig Dermatol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-018-2241-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2241-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2241-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T10:45:07Z","timestamp":1589625907000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-018-2241-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,6]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2241"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2241-x","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,6]]},"assertion":[{"value":"22 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the ethical standards of the 1964 Helsinki Declaration and its later amendments. This study was deemed exempt from Partners Healthcare\u2019s IRB review (2018P001413) and for this type of study formal consent is not required. There were no human participants, procedures, animal experiments, or cell line experiments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}